Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialEdward A Stadtmauer, Marcelo C Pasquini, Beth Blackwell, et al.
Nature Medicine|July 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trialAdam D Cohen, Joshua Richter, Suzanne Trudel, et al.
Blood Advances|October 23, 2020
Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumabAmrita Krishnan, Vikram Adhikarla, Erasmus K Poku, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyThomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
Medical Physics|April 30, 2022
Toward automatic beam angle selection for pencil-beam scanning proton liver treatments: A deep learning-based approachRobert Kaderka, Keng-Chi Liu, Lawrence Liu, et al.
JCI Insight|January 19, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myelomaHadas Lewinsky, Emine G Gunes, Keren David, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Scientific Reports|August 22, 2019
Two Isoforms of the Guanine Nucleotide Exchange Factor, Daple/CCDC88C Cooperate as Tumor SuppressorsJason Ear, Ying Dunkel, Yash Mittal, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Quantification of Modifiable Risk Factors in Monoclonal Gammopathy of Undetermined Significance Progression to Multiple MyelomaMei Wang, Byron Sigel, Lawrence Liu, et al.
Leukemia|April 17, 2020
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targetingDomenico Viola, Ada Dona, Enrico Caserta, et al.
Pageof 16